Dr. Allen C. Ho is a Phi Beta Kappa graduate of Cornell University College of Arts and Sciences, receiving highest distinction in all subjects. He graduated from Columbia University College of Physicians and Surgeons and was elected Co-Chief Resident during his ophthalmology residency at Wills Eye Hospital. He completed a Fellowship in Vitreoretinal Diseases at Manhattan Eye, Ear and Throat Hospital where he was awarded a Heed Ophthalmic Fellowship. Dr. Ho is Board Certified in Ophthalmology, an Associate Examiner for the American Board of Ophthalmology and a Fellow in the American College of Surgeons. He is an active member in several ophthalmologic societies including: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, The American Society of Retina Specialists, The Macula Society, The Retina Society, The Society of Heed Fellows, and the Pennsylvania Academy of Ophthalmology. Dr. Ho joined Retinovitreous Associates in April, 1999. He is Professor of Ophthalmology at Thomas Jefferson University School of Medicine. Dr. Ho has authored numerous scientific publications on retinal disease, is author of The Wills Eye Hospital Color Atlas and Synopsis of Retinal Disease, and is a member of the Editorial Review Boards of Ophthalmic Surgery, Lasers and Imaging and Ophthalmology Times. He is Editor-in-Chief of Current Opinion in Ophthalmology and has been an invited lecturer at numerous national and international ophthalmic meetings. He is a recipient of several clinical research grants investigating new treatments for macular diseases sponsored by the National Eye Institute and received the American Academy of Ophthalmology's Achievement Award. He is an invited Advisory Board member for the Alcon Vitreoretinal Surgical Advisory Committee and the Ophthalmic Devices Committee of the United States Food and Drug Administration. Dr. Ho is the Principal Investigator at Wills Eye Hospital of several collaborative clinical trials evaluating new treatments for age-related macular degeneration and diabetic retinopathy and maintains special interests in macular diseases, diabetic retinopathy, surgical retinal diseases and clinical trials investigating new treatments for vitreoretinal diseases. Dr. Ho was named to "Best Doctors in America" and "Top Doctors of Philadelphia" as elected by peer physicians.
|
CURRICULUM VITAE Allen C. Ho, MD FACS
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Office Address: |
Retinovitreous Associates
Wills Eye Institute |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Birthdate / Place: | March 13, 1962 Minneapolis, Minnesota | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Education: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Postgraduate and Fellowship Training: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Specialty Certification: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Licensure: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Awards, Honors and Membership in Honorary Societies: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Academic and Administrative Appointments: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Scientific and Investigative Positions: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Academic and Industry Advisory Boards: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Academic Committees: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Memberships in Professional and Scientific Societies: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lectures by Invitation and Presentations (Partial): | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Invited lecturer at the University of Maryland's New Treatments for Age-Related Macular Degeneration Course in Baltimore, Maryland on September 22, 2000. Laser to Drusen: Is there enough evidence to support this treatment? Invited speaker Retina 2001, New Treatments for Age-Related Macular Degeneration and Complex Diabetic Traction Retinal Detachment Surgery with an Illuminated Diamond Knife. New England Eye Center, January 2001. Invited speaker for the First Annual Applications of Verteporfrin (Visudyne) for Age-Related Macular Degeneration in Scottsdale, Arizona, on April 7, 2001. Invited speaker on New Treatments for Age-related Macular Degeneration at the Pan American Academy of Ophthalmology in Buenos Aires, Argentina, on July 2001. Invited speaker to the Saint Vincent / Catholic Medical Center to speak on Posterior Segment Manifestations of Ocular Trauma and Prophylactic Treatment for High Risk Unilateral AMD, on October 4, 2001. Invited speaker to the Ocular Drug Delivery Meeting sponsored by the Foundation for Fighting Blindness on October 26th and 27th, 2001 in San Francisco, California. Sustained release intravitreal fluocinolone acetonide in combination with low intensity laser for dry AMD. Invited speaker to the Retina 2001, Subspecialty Conference at the American Academy of Ophthalmology on November 8, 2001. Laser Treatment of Drusen in AMD. Invited lecturer at the Greater New York Ophthalmology Clinical Lecture Series, Manhattan Eye and Ear Hospital on January 16, 2002: "Retinal Vascular Disease" and "New Approaches to High Risk Dry Age-Related Macular Degeneration". Invited lecturer at the Aspen Retinal Detachment Society March 3- 6, 2002. "Surgical Pearls for Wide Angle Viewing Vitreoretinal Surgery" and "Pharmacosurgical Intervention for Unilateral High Risk Dry Age-Related Macular Degeneration". Invited lecturer at the New York State Ophthalmologic Society Annual Meeting in Stowe Vermont on February 9, 2002: "Update on Macular Hole: Classification and Surgery" and "Laser to Drusen". Invited lecturer at the Northshore / Long Island Jewish Health System Clincal Ophthalmology Day on March 27, 2002. "Retinal Vascular Diseases: New Approaches and Updating Your Work-Up" and "New and Investigational Treatments for Age-Related Macular Degeneration". Invited lecturer at the 1st Annual Bluegrass Ophthalmology meeting at the University of Kentucky, Lexington April 12 -13, 2002. Potential Prophylactic Therapies for Age-related Macular Degeneration. Invited lecturer at the SUNY Ophthalmology Alumni Day in Brooklyn, NY on June 20, 2002. New Approaches to Retinal Vascular Diseases. Invited lecturer at Macula 2003, Manhattan Eye and Ear, New York, NY on January 17, 2003. High Speed Low Flow Vitrectomy for Diabetic Traction Retinal Detachment. Invited lecturer at the Current Concepts in Ophthalmology, Johns Hopkins University Wilmer Eye Institute, Vail Colorado March 18 – 22, 2003. Anecortave Acetate for Age-related Macular Degeneration; High Speed Low Flow Vitrectomy for Diabetic Traction Retinal Detachment. Invited lecturer at the New Jersey Retinal Society in Essex, NJ on September 23, 2003. High Speed Low Flow Vitrectomy for Diabetic Traction Retinal Detachment. Invited lecturer at Vail Vitrectomy 2004, Vail Colorado. Risk Factors for CNV and Prevention Trials for Age-related Macular Degeneration. Invited lecturer at the Current Concepts in Ophthalmology, Johns Hopkins University Wilmer Eye Institute, Vail Colorado March 2004. Games and Sports Related Ocular Trauma; Anecortave Acetate for Age-related Macular Degeneration. Invited lecturer at the Cincinnati Ophthalmic Society, April 2004. 25 Gauge Vitrectomy in Evolution; Risk Factors for Choroidal Neovascularization and AMD. Invited lecturer at the New Mexico TriState Ophthalmological Meeting, Santa Fe NM May 2004. Prevention Therapies for AMD. Invited lecturer at the Washington Hospital Retina Meeting, Perraut Lecture, Washington DC October 2004. Risk Factors for Choroidal Neovascularization. Invited lecturer at the Delaware Ophthalmological Meeting, Wilmington DE November 2004. Anti VEGF Therapies for AMD. Invited lecturer at Retina 2005 Meeting, Kona HI January 2005. Anti VEGF Therapies for AMD, New Illumination for Vitreoretinal Surgery, Prevention Therapies for AMD. Invited lecturer at the Angiogenesis 2005 Meeting, Naples FL February 2005. Lucentis for Exudative AMD. Invited lecturer at the Aspen Retinal Detachment 2005 Meeting, Aspen CO March 2005. Anti VEGF Therapies for AMD, New Illumination for Vitreoretinal Surgery, OCT Imaging and Vitreomacular Surgery Invited lecturer at the Johns Hopkins Current Concepts of Ophthalmology 2005 Meeting, Vail CO March 2005. Anti VEGF Therapies for AMD, New Illumination for Vitreoretinal Surgery, Prevention Therapies for AMD. Invited lecturer at the New England Eye Center 2005 AMD Meeting, Boston MA April 2005. Anti VEGF Therapies for AMD, Prevention Therapies for AMD. Television panelist for the White Paper Roundtable on AMD 2005 Meeting, Chicago 2005. Television Studio Production. Invited Visiting Professor for Grand Rounds Manhattan Eye, Ear and Throat Hospital, New York NY May 2005. Retina Fundamentals: Case Presentations and Anti-VEGF Therapies for AMD. Invited lecturer at the 38th Annual Panhellenic Ophthalmogical 2005 Meeting, Mykonos Greece May 2005. Prevention Therapies and Laser to Drusen for AMD. Invited Lecturer at the Eye Research Institute / Wills Retina Meeting 2005 in Lake Louise Canada. Anti VEGF Therapies for Age Related Macular Degeneration. Invited Lecturer at the American Society of Retina Specialists Annual Meeting in Montreal Canada July 2005. Improving Task Specific and Wide Angle Illumination during Vitreous Surgery. Retina Section program director for 14hAnnual Ocular Surgery News Symposium, New York October 2005., New Developments in Retina 2005. Invited Lecturer at the Retinal Education and Advisory Meeting in Shanghai, China September 2005, Safe and Improved Wide Angle Illumination during Vitreous Surgery. Invited Lecturer at the Japanese Advanced Vitreoretinal Surgery Course in Tokyo, Japan September 2005. Prevention Trials for Age Related Macular Degeneration and Safe and Improved Wide Angle Illumination during Vitreous Surgery. Senior course instructor for New and Investigational Therapies for Age Related Macular Degeneration at the American Academy of Ophthalmology 2005 Meeting in Chicago. Visiting Professor at the Genentech EyeQ Visiting Professor Program November 2005 San Francisco. The New Order 2005: Age Related Macular Degeneration Therapies in Evolution. Invited Lecturer at the Macula 2006 Meeting in New York January 2006, Xenon Illumination and Bimanual Surgery. Invited Lecturer at Retina 2006 Meeting in Maui January 2006, Current and future anti-VEGF therapy for AMD, 25g Vitrectomy Surgery, OCT Imaging and Macular Surgery. Invited Lecturer at Squaw Valley Retina 2006 Meeting in Lake Tahoe California January 2006, Xenon Illumination and Bimanual Surgery, Anti-VEGF mechanisms of action for AMD. Invited Lecturer at the Macula Society 2006 Meeting in Aviara California February 2006, The MARINA Study: Subanalysis for AMD. Invited Lecturer at the Aspen Retinal Detachment Society 2006 Meeting in Colorado March 2006, Anti-VEGF therapy for AMD, Improved Wide Angle Vitrectomy Illumination and Bimanual Surgery. Invited Lecturer at the Spanish Vitreoretinal Society 2006 Meeting in Barcelona March 2006, Prevention Trials in Age Related Macular Degeneration , Anti-VEGF therapy for AMD, Improved Wide Angle Vitrectomy Illumination and Bimanual Surgery. Kunimoto DY, Ko G, Vander JF, Ho AC, Sivalingam A., Benson WE. Location Of Open Globe Wounds In Patients With Prior Intraocular Surgery. ARVO 2006. Hsu J, Kaiser RS, Sivalingam A., Abraham P, Fineman MS, Samuel MA, Vander, JF, Ho AC Intravitreal Bevacizumab (Avastin) In Central Retinal Vein Occlusion. ARVO 2006. Gupta OP, Weichel ED, Fineman MD, Regillo CD, Kaiser RS, Ho AC, McNamara JA, Vander, JF. Postoperative Complications Associated With 25-Gauge Pars Plana Vitrectomy. ARVO 2006. Chen E, Ho AC. Initial Results of Retinal Detachment Surgery Using Perfluorocarbon Liquid as a Postoperative Ocular Endotamponade. ARVO 2006. Chhabra S, Kunimoto DY, Regillo CD, Ho AC, Belmont J, Maguire J, Brown GC. The Microbiologic Spectrum of Endophthalmitis After Open Globe Injuries. ARVO 2006. Invited Lecturer at Evolutions and Revolutions: Retina 2006 Meeting Tufts New England Medical Center in Boston April 2006, The New Order: Other AntiVEGF therapies for AMD. Invited Lecturer at the Cole Eye Institute Retina 2006 Meeting, Cleveland Clinic Medical Center May 2006, Prevention Trials in Age Related Macular Degeneration , Anti-VEGF therapy for AMD, Anti-VEGF therapy for Diabetic Retinopathy. Invited Lecturer at the Retinal Physician 2006 Symposium, Nassau, Prevention Trials in Age Related Macular Degeneration, MP1, PHP, etc...Moving Beyond the Amsler Grid. Invited Lecturer at the Advanced Vitreoretinal Technology and Therapies 2006 Symposium, Chicago, The Role of OCT in Macular Surgery, New Instrumentation for Vitrectomy Surgery 2006, Moving Beyond the Amsler (PHP), Anecortave Acetate Update 2006 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bibliography: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Lieb WE, Flaharty PM, Ho AC, Sergott RC. Color Doppler imaging of the eye and orbit: A synopsis of a 400 case experience. ACTA Ophthalmol 1992; 204: 50-54. Ho AC, Lieb WE, Flaharty PM, Brown GC, Bosley TM, Savino PJ, Sergott RC. Color Doppler imaging of the ocular ischemic syndrome. Ophthalmology 1992; 99: 1453-1462. Sergott RC, Flaharty PM, Lieb WE, Ho AC, Kay MD, Mittra RA, Savino PJ, Bosley TM. Color Doppler imaging identifies four syndromes of the retrobulbar circulation in patients with amaurosis fugax and central retinal artery occlusions. Trans Am Ophth Soc 1992; 90: 383-398. Ho AC, Guyer DR, Yannuzzi LA, Brown GC. Ocular syphillis: Classic manifestations and recent observations. Sem in Ophthalmol 1993; 8: 53-60. Ho AC and Rapuano CJ. Pasteurella multocida keratitis and corneal laceration by cat scratch. Ophthal Surg 1993; 24: 346-348. Regillo CD, Sergott RC, Ho AC, Belmont JB, Fisher DH. Hemodynamic alterations in the acute retinal necrosis syndrome. Ophthalmology 1993; 100: 1171-6. Ho AC, Yannuzzi LA, Guyer DR, Sorenson JA, Slakter JA , Orlock DA. Intraretinal accumulation of indocyanine green dye in age-related macular degeneration. Ophthalmology 1994; 101: 534-541. Ho AC, Fisher YL, Slakter JS, Guyer DR, Sorenson JA, Yannuzzi LA. Intraoperative real-time indocyanine green videoangiography in subretinal surgery. Arch Ophthalmol 1994; 112: 872-874. Slakter JS, Yannuzzi LA, Sorenson JA, Guyer DR, Ho AC, Orlock D. A pilot study of digital indocyanine green videoangiography-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 1994; 112: 465-72. Sorenson JA, Yannuzzi LA, Slakter JS, Guyer DR, Ho AC, Orlock D . A pilot study of digital indocyanine green videoangiography for recurrent choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 1994; 112: 473-9. Ho AC, Sergott RC, Regillo CD, Savino PJ, Lieb WE, Flaharty PM, Bosley TM. Color Doppler hemodynamics of giant cell arteritis. Arch Ophthalmol 1994; 112: 938-945. Yannuzzi LA, Hope-Ross M, Slakter JS, Guyer DR, Sorenson JA, Ho AC, Sperber DE, Freund KB, Orlock D. Analysis of vascularized pigment epithelial detachment using indocyanine green videoangiography. Retina 1994; 14: 99 -113. Moadel K, Yannuzzi LA, Ho AC, Ursekar A. Retinal vascular occlusive disease in a child with neurofibromatosis. Arch Ophthalmol 1994; 112: 1021 - 3. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho AC, Orlock D. Indocyanine green videoangiography of central serous choroidopathy. Arch Ophthalmol 1994; 112: 1057 - 62. Goebel W, Lieb WE, Ho AC, Sergott RC, Farhouman R, Grehn F. Color Doppler imaging: a new technique to assess orbital blood flow in patients with diabetic retinopathy. Invest Ophthalmol & Visual Science 1995; 36: 864 - 870. Ho AC, Pisacano K, Yannuzzi LA, DeRosa JT. The natural history of idiopathic subfoveal choroidal neovascularization. Ophthalmology 1995; 102: 782 - 789. Ho AC, Maguire AM, Yannuzzi LA, Fisher YL, Galetta S, Fisher YL, Sergott RC. Rapidly progressive optic disc neovascularization after diabetic papillopathy. Am J Ophthalmol 1995; 120: 673 - 675. Mousa SA, Kerr JS, Ho AC. Angiogenesis in Vascular Disorders. Current Research in Vascular Diseases 1997; 3: 1 - 5. Choroidal Neovascularization Prevention Trial Study Group. Laser Treatment in Eyes with Large Drusen: Short Term Effects from a Pilot Randomized Clinical Trial. Ophthalmology 1998; 105: 11-23. Choroidal Neovascularization Prevention Trial Study Group. Choroidal neovascularization in the CNVPT. Ophthalmology 1998; 105: 1364 - 1372. Ho AC, Guyer DR, Fine SL. Macular Hole. Survey Ophthalmology 1998; 42: 393 - 416. Grunwald JE, Hariprasad S, Dupont J, Maguire MG, Fine SL, Brucker AJ, Maguire AM, Ho AC. Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1998; 39: 385 - 390. Ho AC, Maguire MG, Yoken J, Lee ML, Shin DS, Javornik NB, Fine SL and the Choroidal Neovascularization Prevention Trial Study Group.. Laser induced drusen reduction improves visual function at 1 year. Ophthalmology 1999; 106: 1367 - 1374. Sharma MC, Ho AC. Macular fibrosis associated with talc retinopathy. Am J Ophthalmol 1999; 128: 517 – 519. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med 2000; 342: 483 - 492. Owsley C, Jackson GR, Cideciyan AV, Huang Y, Fine SL, Ho AC, Maguire MG, Lolley V, Jacobson SG. Psychophysical evidence for rod vulnerability in age-related macular degeneration. Invest Ophth Vis Sci 2000; 41: 267 - 273. Kaiser RS, Maguire MG, Grunwald JE, Lieb D, Jani B, Brucker AJ, Maguire AM, Ho AC, Fine SL. One-Year outcomes of panretinal photocoagulation in proliferative diabetic retinopathy. Am J Ophthalmol 2000; 129: 178 – 185. Ho AC, Benson WE, Wong J. Unusual Immunogammopathy Maculopathy. Ophthalmology 2000; 107: 1099 – 1103. Recchia F, Ho AC. Laser treatment of retinal venous occlusive disease. Comprehensive Ophthalmology 2000; 1: 109 – 118. Vander JF, Ho AC, McNamara JA, Regillo CD, Brown GC, Benson WE, Tasman W. Diabetes and retinopathy. Ophthalmology. 2000 Dec;107(12):2120-2. Kaiser RS, Berger JW, Maguire MG, Shin DS, Ho AC, Javornik NB, Fine SL and the Choroidal Neovascularization Prevention Trial Research Group. Laser burn intensity and the risk for choroidal neovascularization in the CNVPT Fellow Eye Study. Arch Ophthalmol 2001; 119:826-832. Benson WE, Regillo CD, Vander JF, Tasman W, Smith AF, Brown GC, Ho AC, McNamara JA. Patient initiated second medical opinions: Their necessity and economic cost. Retina 2001; 21: 633 – 638. Shuler MF, Borrillo JL, Ho AC. Photodynamic therapy update. Curr Opin Ophthalmol 2001, 12(3):202-6. Ho AC and Regillo CD. Clinical Challenges Commentary. Bilateral Retinal Hemorrhages in an 18 year old woman. Surv Ophthalmol 2002: 47: 590 – 593.
Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina. 2003;23(1):14-23. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology. 2003: 110:979-86. Nagra P, Ho AC, Dugan JD. Lipemia Retinalis Associated with Branch Retinal Vein Occlusion. Am J Ophthalmol 2003: 135: 539 – 542. Sharma, MC, Ho, AC. Agreement Among Ophthalmologists in Evaluating Fluorescein Angiograms in Patients with Neovascular Age-Related Macular Degeneration for Photodynamic Therapy Eligibility (Flap-Study). Review. Evidence-Based Eye Care 2003, 4(3):162-163. Maguire MG, Ying G-S, Javornik NB, Ho AC, Fine SL for the Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Ophthalmology. 2003;110(5):971-8. Ho AC. " Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin Therapy of Subfoveal CNV in Patients with AMD: Additional Information Regarding Baseline Lesion Composition’s Impact on Vision Outcomes – TAP Report No. 3.” Review. Evidence-Based Eye Care 2003, 4(2):70-71. Prenner JL, Rosenblatt BJ, Tolentino MJ, Ying G-S, Javornik NB, Maguire MG, Ho AC and the CNVPT Research Group. Risk Factors for Choroidal Neovascularization and Vision Loss in the Fellow Eye Study of the CNVPT. Retina 2003; 23: 307 – 314. Ho AC . “ Seddon JM, Cote J, Davis N, Rosner B. Progression of Age-Related Macular Degeneration: Association with Body Mass Index, Waist Circumference, and Waist-Hip Ratio. Arch Ophthalmol 2003; 121: 785 - 792.” Evidence-Based Eye Care 2003, 4(4):202-203. Ho AC. “Effect of Lesion Size, Visual Acuity, and Lesion Composition on Visual Acuity Change With and Without Verteporfin Therapy for CNV Secondary to AMD: TAP and VIP Report No. 1. Am J Ophthalmol 2003; 136: 407 – 418. Evidence-Based Eye Care 2004, 5(1):13-15. Liu M, Lee H, HertelR, Ho AC. Retinal Detachment From Inadvertent Intraocular Injection of Botulinum Toxin A. Am J Ophthalmol. 2004 Jan;137(1):201-2. Lee HC, Liu M, Ho AC. Idiopathic Juxtafoveal Telangiectasis in Association With Celiac Sprue. Arch Ophthalmol. 2004;122:411-413. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of neovascularization in age-related macular degeneration (AMD): twelve month clinical outcomes. Retina. 2003;110(1):2372 -83. VAM Study Writing Committee (Ho AC, Writing Committee Chairman). Verteporfin Therapy in Age-Related Macular Degeneration (VAM): An Open-label Multicenter Photodynamic Therapy Study of 4,435 Patients. Retina. 2004 Aug;24(4):512-520. Gragoudos ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR and the VEGF Inhibition Study in Ocular Neovascularization Study Group. Pegaptanib for Neovascular Age-Related Macular Degeneration. N Engl J Med 2004: 351: 2805 - 2816. Ho AC. Effect of Lesion Size, Visual Acuity, and Lesion Composition on Visual Acuity Change With and Without Verteporfin Therapy for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: TAP and VIP Report No. 1. Critical Review. Evid Based Ophthalmol 2004. Smith BT, Belani S, Ho AC. Light energy, cataract surgery, and progression of age-related macular degeneration. Curr Opin Ophthalmol. 2005 Jun;16(3):166-9 Smith BT, Belani S, Ho AC. Ultraviolet and near-blue light effects on the eye. Int Ophthalmol Clin. 2005 Winter;45(1):107-15. Recchia FM, Busbee BG, Pearlman RB, Carvalho-Recchia CA, Ho AC. Changing trends in the microbiologic aspects of postcataract endophthalmitis. Arch Ophthalmol. 2005 Mar;123(3):341-6 Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D’Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD, Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005 Oct;112(10):1747-57. Ho AC. Photodynamic Therapy with Verteportin combined with Intravitreal Injection of Triamcinolone Acetonide for Choroidal Neovascularization. Critical Review. Evid Based Ophthalmol 2005. Hurley BR, McNamara JA, Fineman MS, Ho AC, Tasman W, Kaiser RS, Vander JF, Regillo CD. Laser Treatment for Retinopathy of Prematurity: Evolution of Treatment Technique over 15 years.. Retina. 2006 Sep;26. Lam A, Lee HC, Ho AC, Regillo CD, McNamara JA, Fineman MD. Photodynamic therapy in young patients. Ophthalmic Surg Lasers Imaging. 2006 May-Jun;37(3):182-9. Smith BT, Vander JE, Regillo CD, Ho AC. Evaluation of the potential acuity meter in predicting visual acuity after photodynamic therapy for choroidal neovascularization. Ophthalmic Surg Lasers Imaging. 2006 Jan-Feb;37(1):6-11. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Year 2 Efficacy Results of 2 Randomized Controlled Clinical Trials of Pegaptanib for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2006 Jun;113(6):992-1001 y. D'Amico DJ; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group; Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006 Jun;113(6):1001.e1-6. Rodrigues EB, Rossi EE, Grumann Junior A, Meyer CH, Ho AC. Treatment of neovascular age-related macular degeneration with antiangiogenic drugs. Arq Bras Oftalmol. 2006 Sep-Oct;69(5):756-65. Weichel ED, Martidis A, Fineman MS, McNamara JA, Park CH, Vander JF, Ho AC, Brown GC. Pars plana vitrectomy versus combined pars plana vitrectomy-scleral buckle for primary repair of pseudophakic retinal detachment. Ophthalmology. 2006 Nov;113(11):2033-40. Fintak DR, Ho AC. Perioperative and operative considerations in diabetics. Ophthalmol Clin North Am. 2006 Dec;19(4):427-34. Chhabra S, Kunimoto DY, Kazi L, Regillo CD, Ho AC, Belmont J, Maguire J, Vander J, Brown GC. Endophthalmitis after open globe injury: microbiologic spectrum and susceptibilities of isolates. Am J Ophthalmol. 2006 Nov;142(5):852-4. Hurley BR, McNamara JA, Fineman MS, Ho AC, Tasman W, Kaiser RS, Vander JF, Regillo CD, Brown GC. Laser Treatment for Retinopathy of Prematurity: Evolution in Treatment Technique Over 15 Years. Retina. 2006 Sep;26(7 Suppl):S16-7. Aizman A, Johnson MW, Olsen TW, Ho AC, Davis JL. Diagnostic and therapeutic challenges. High grade fever and bronchitis. Retina. 2006 Mar;26(3):345-51. CAPT Study Group . Laser Treatment in Patients with Bilateral Drusen. The Complications of AMD Prevention Trial. Ophthalmol 2006; 113: 1974 – 1986. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP,Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non Peer-Reviewed Original Books, Reviews and Chapters: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Ho AC. Wills Eye Hospital Office and Emergency Room Treatment of Eye Disease. Second Edition. Retina Section Contributing author. JB Lippincott, Philadelphia 1994. Ho AC and Guyer DR. Subfoveal choroidal neovascularization and indocyanine green dye-enhanced laser photocoagulation. In: Benson WE, Coscas G, Katz LJ Current Techniques in Ophthalmic Laser Surgery 1995; Current Medicine, Philadelphia. Ho AC. Clinical Retinopathies. Dodson PM, Gibson JM, and Kritzinger EE. (Review) Ophthalmic Surgery and Lasers 1995; 26: 584. Ho AC. Age-related macular degeneration: Where are we and where do we need to go? Review of Ophthalmology 1995; 2: 55 - 67. Ho AC. An experimental therapy for age-related macular degeneration: thalidomide. Review of Ophthalmology 1995; 2: 55 - 64. Ho AC. Clinical Decisions in Medical Retinal Diseases. Tasman, WS (editor) (Review) Ophthalmic Surgery and Lasers 1996; 27: 158 - 159. Ho AC. Indocyanine Green Dye Imaging of the Retina and Retinal Vascular Diseases. (Chapter) in Yannuzzi LA (ed) Indocyanine Green Videoangiography. CV Mosby, St Louis 1997. Ho AC. Age-Related Macular Degeneration. Current Concepts in Ophthalmology 1998; 5: 44 - 48. Ho AC. Wills Eye Hospital Atlas of Clinical Ophthalmology. Tasman, WS and Jaeger EA (editors) and Atlas of Clinical Ophthalmology. Albert, DM and Jakobiec FA (editors). (Review) Ophthalmic Surgery and Lasers 1998; 29: 167 - 168. Ho AC. Macular Hole, in Vitreous - Retina - Macula, Guyer DR, Yannuzzi LA, Chang S, Shields J, Green WR (editors) WB Saunders, Philadelphia 1998. Ho AC, Guyer DR, Fine SL. Clinical Examination of the Posterior Segment of the Eye, in Vitreous - Retina - Macula. Guyer DR, Yannuzzi LA, Chang S, Shields J, Green WR. (editors), WB Saunders, Philadelphia 1998. Ho AC. Hemoglobinopathies, in Ophthalmology. Yanoff M, Duker J et al (editors), Mosby, London 1998. Ho AC. Miscellaneous Macular Diseases. Brown GC, Flynn HW, and Regillo CD, (editors). Essentials of Vitreoretinal Disease. Thieme, London. 1998. Ho AC. Laser Treatment of Eyes with Drusen in Current Concepts in Ophthalmology by GC Brown, (editor) 1999. Ho AC. New and Investigational Therapies for Age-Related Macular Degeneration. The Panretinal View. Ophthalmology Times 1999. Ho AC. Ocular Toxoplasmosis (review). Evidence Based Eye Care 2000. Ho AC. Macular Hole. Tasman W (editor) Spaeth’s Ophthalmic Surgery, 4th edition, 2000. Sung J, Ho AC. Macular Pucker. Tasman W (editor) Spaeth’s Ophthalmic Surgery, 4th edition, 2000. Connolly BP, Ho AC. Essentials of the funduscopic examination. Clinics Atlas of Office Procedures , Maus M, Jeffers J, Holleran E eds., WB Saunders Philadelphia, 2000. Ho AC. "A Preliminary Study of Photodynamic Therapy Using Verteporfin for Choroidal Neovascularization in Pathologic Myopia, Ocular Histoplasmosis Syndrome, Angioid Streaks and Idiopathic Causes". (review) Evidence Based Eye Care 2000. Shuler MF, Borillo L, Ho AC. Photodynamic Therapy for Age-Related Macular Degeneration. Current Opinion in Ophthalmology 2001. Ho AC. "How to Use the Instruments For Examination of the Posterior Segment". Clinical Pathways in Vitreoretinal Disease, Steidl S and Hartnett M eds., Thieme Publishers, New York 2001. McCabe F, Ho AC. Vein Occlusion: Current and Future Therapies. Review of Ophthalmology 12: 2001. McCabe F and Ho AC. Argon Laser to Drusen . Lim J (editor) Age-Related Macular Degeneration. Marcel Drekker, 2002. Ho AC and Lee HC. Macular Hole. Tasman W and Jaeger E (editors) Duane’s Clinical Ophthalmology, Lippincott Williams Wilkens, Philadelphia 2002. Stein J, Brown GC, Ho AC. Fluorescein Angiography for Retinal Vascular Diseases. Tasman W and Jaeger E (editors) Duane’s Foundations of Clinical Ophthalmology, Lippincott Williams Wilkens, Philadelphia 2002. Ho AC, Brown GC, McNamara JA, Recchia FM, Regillo CR, Vander JF. Retina. Color Atlas and Synopsis of Clinical Ophthalmol ogy. McGraw Hill, New York 2003. Ho AC. Hemoglobinopathies. Ophthalmology. Yanoff M, Duker J et al (editors), Mosby, London 2003. Garg S, Ho AC. Retinal Arterial Obstructive Disease. Atlas of Posterior Segment Imaging. Kaiser P (editor) Elsevier, Philadelphia 2003. Ho AC. Retsumer Report: Vitrectomy Machines/Systems. Retina Times, American Society of Retina Specialists, 2003; 22-25. Ho AC. Age-Related Macular Degeneration: Current and Emerging Treatments. Foresight 2003: 1, 1 – 11. Ho AC. Prevention Strategies for Age-Related Macular Degeneration: New Perspectives. Ocular Surgery News, 2004. Ho AC. Prevention Therapies for Age-Related Macular Degeneration. Letter to the Editor. Primary Care Optometry News, 2004. Puliafito C, Ho AC, Slakter J, Rosenfeld P. New Perspectives on Age-Related Macular Degeneration. Ocular Surgery News, 2005. Duker J and Ho AC. Saving the Eyesight of Diabetic Patients Begins at Diagnosis. Endocrine Today, 2005. Ho AC. Complication of Botox Injection: Subretinal Botox Injection. Dermatology News, 2005. Ho AC, Johnson M, Saperstein D, Williams G. Treating Neovascular Age-Related Macular Degeneration: An Evidence-Based Guide to Therapy by Lesion Type. Ophthalmology Times, 2005. Ho AC. Anecortave Acetate: Treatment for Age-Related Macular Degeneration. Retinal Physician, 2005. Kaiser R and Ho AC. Review of Ocular Angiogenesis and New Therapies for Choroidal Neovascularization. Ophthalmology Times 2005. Schachat A, D’Amico D, Gragoudas E, Ho AC, Regillo CD, Rosenfeld P. Age-Related Macular Degeneration Prevention and Therapy. Johns Hopkins CME Press 2005. Charles S, Ho AC, Packo K, Regillo CD. 25 Gauge Vitrectomy Roundtable Discussion. Ophthalmology Times 2005. Ho AC. Safe and Brighter Endoillumination for Vitrectomy Surgery. Retina Times, 2005. Bressler N, Heier J, Ho AC, Williams G. Clinical Advances in AMD 2006 Update. Managing Patients’ and Physicians’ Expectations in the Treatment of AMD. Johns Hopkins CME Press, 2006. Fintak DR and Ho AC. Perioperative and Operative Considerations in Diabetics. Ophthalmol Clin N Am 2006: 427 – 434. Ho AC, Reichel E, Ip M, Schachat A. OCT Guided Therapy of AMD . Retinal Physician Ho AC, Boyer D, Kaiser P, Charles S. New Advances in Microincision Vitrectomy Surgery. Retinal Physican |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
